Maternal immunization: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:
Inactivated influenza and combined tetanus-diphteria-acellular pertussis (TDaP) are recommended for pregnant women in the U.S. Hepatitis B and hepatitis E vaccines are recommended in some other countries.<br>
Inactivated influenza and combined tetanus-diphteria-acellular pertussis (TDaP) are recommended for pregnant women in the U.S. Hepatitis B and hepatitis E vaccines are recommended in some other countries.<br>
The following table summarize the vaccines and current recommendations for their administration during pregnancy.
The following table summarize the vaccines and current recommendations for their administration during pregnancy.
{| class="wikitable"
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
! colspan="2" rowspan="2" |Vaccine
! colspan="2" rowspan="2" align="center" style="background:#DCDCDC;"|Vaccine
! rowspan="2" |Type
! rowspan="2" align="center" style="background:#DCDCDC;"|Type
! rowspan="2" |Recommendation for pregnant women
! rowspan="2" align="center" style="background:#DCDCDC;"|Recommendation for pregnant women
! colspan="2" |Specific consideration
! colspan="2" align="center" style="background:#DCDCDC;"|Specific consideration
|-
|-
!Category
!align="center" style="background:#DCDCDC;"|Category
!Comment
!align="center" style="background:#DCDCDC;"|Comment
|-
|-
| colspan="2" |Anthrax
| colspan="2" align="center" style="background:#DCDCDC;"|Anthrax
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|May be used in women with high risk of exposure; not recommended for
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |May be used in women with high risk of exposure; not recommended for
those with low risk of exposure.
those with low risk of exposure.
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|Generally, inactivated vaccines are safe in pregnancy but anthrax vaccine is reserved for high risk mothers only.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Generally, inactivated vaccines are safe in pregnancy but anthrax vaccine is reserved for high risk mothers only.
|-
|-
| colspan="2" |BCG
| colspan="2" align="center" style="background:#DCDCDC;"|BCG
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|Contraindicated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Contraindicated
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|Live vaccines are contraindicated in pregnancy however, there is no report for BCG adverse effects in pregnancy
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live vaccines are contraindicated in pregnancy however, there is no report for BCG adverse effects in pregnancy
|-
|-
| colspan="2" |HAV
| colspan="2" align="center" style="background:#DCDCDC;"|HAV
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Recommended for specific indications
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended for specific indications
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Indications:
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Indications:
* History of injection or noninjection illicit drug use
* History of injection or noninjection illicit drug use
* Work with HAV-infected primates
* Work with HAV-infected primates
Line 45: Line 45:
* Travel to or work in countries with high or intermediate endemicity of hepatitis A
* Travel to or work in countries with high or intermediate endemicity of hepatitis A
|-
|-
| colspan="2" |HBV
| colspan="2" align="center" style="background:#DCDCDC;"|HBV
|Recombinant
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recombinant
|Recommended for specific indications
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended for specific indications
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Indications:
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Indications:
* If have had a HBsAg-positive sex partner
* If have had a HBsAg-positive sex partner
* Have had more than one sex partner during the previous 6 mo
* Have had more than one sex partner during the previous 6 mo
Line 56: Line 56:
The recommended schedule is 0, 1, and 6 mo.
The recommended schedule is 0, 1, and 6 mo.
|-
|-
| colspan="2" |HPV
| colspan="2" align="center" style="background:#DCDCDC;"|HPV
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Not recommended
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Not recommended
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|If a woman is found to be pregnant during the administration of an HPV series, the remaining doses should be delayed until after pregnancy is completed.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |If a woman is found to be pregnant during the administration of an HPV series, the remaining doses should be delayed until after pregnancy is completed.
|-
|-
| colspan="2" rowspan="2" |Influenza
| colspan="2" rowspan="2" align="center" style="background:#DCDCDC;"|Influenza
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Recommended
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Recommended for all women who are or will be pregnant during influenza season.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended for all women who are or will be pregnant during influenza season.
|-
|-
|Live, attenuated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live, attenuated
|Contraindicated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Contraindicated
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Risk of fetal infection
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Risk of fetal infection
|-
|-
| colspan="2" |Japanese encephalitis virus
| colspan="2" align="center" style="background:#DCDCDC;"|Japanese encephalitis virus
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Inadequate data for specific recommendation
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inadequate data for specific recommendation
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|Theoretical risk for fetus however, it is recommended for pregnant women traveling to a high risk area.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Theoretical risk for fetus however, it is recommended for pregnant women traveling to a high risk area.
|-
|-
| colspan="2" |Meningococcal
| colspan="2" align="center" style="background:#DCDCDC;"|Meningococcal
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Serotype ACWY conjugate vaccine may be used in the case of a specific indication
* Serotype ACWY conjugate vaccine may be used in the case of a specific indication
* Serotype B vaccine administration should be based on a risk–benefit assessment for the patient
* Serotype B vaccine administration should be based on a risk–benefit assessment for the patient
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| colspan="2" |MMR
| colspan="2" align="center" style="background:#DCDCDC;"|MMR
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|Contraindicated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Contraindicated
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Live vaccines are contraindicated during pregnancy.  
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live vaccines are contraindicated during pregnancy.  


If the vaccine is inadvertently given to a pregnant woman, she should be informed of the theoretical risks to the fetus.
If the vaccine is inadvertently given to a pregnant woman, she should be informed of the theoretical risks to the fetus.
Line 97: Line 97:
However, receipt of the vaccine is not an indication for termination of pregnancy.
However, receipt of the vaccine is not an indication for termination of pregnancy.
|-
|-
| rowspan="2" |Pneumococcal
| rowspan="2" align="center" style="background:#DCDCDC;"|Pneumococcal
|Conjugate
|align="center" style="background:#DCDCDC;"|Conjugate
(PCV13)
(PCV13)
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Inadequate data for specific recommendation
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inadequate data for specific recommendation
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
|Polysaccharide
|align="center" style="background:#DCDCDC;"|Polysaccharide
(PPSV23)
(PPSV23)
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Inadequate data for specific recommendation
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inadequate data for specific recommendation
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|It found to be safe in 2nd and 3rd trimesters. But, it seems that it's not effective to prevent infant pneumococcal infection.(19)
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |It found to be safe in 2nd and 3rd trimesters. But, it seems that it's not effective to prevent infant pneumococcal infection.(19)
|-
|-
| colspan="2" |Poliovirus,
| colspan="2" align="center" style="background:#DCDCDC;"|Poliovirus,
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|May be used if needed
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |May be used if needed
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|Indicated for high risk women (travel to endemic area or occupational exposure)
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Indicated for high risk women (travel to endemic area or occupational exposure)
|-
|-
| colspan="2" |Rabies virus
| colspan="2" align="center" style="background:#DCDCDC;"|Rabies virus
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|May be used if needed
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |May be used if needed
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|Post-exposure prophylaxis is indicated.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Post-exposure prophylaxis is indicated.
|-
|-
| colspan="2" |Smallpox
| colspan="2" align="center" style="background:#DCDCDC;"|Smallpox
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|Recommended after exposure
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended after exposure
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|Pre-exposure prophylaxis is not recommended.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Pre-exposure prophylaxis is not recommended.
|-
|-
|TDaP
|align="center" style="background:#DCDCDC;"|TDaP
|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
|align="center" style="background:#DCDCDC;"|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis
|Inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated
|Recommended
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Recommended
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Preferred time: 27-36 weeks although, it can be delivered in any stage of pregnancy
* Preferred time: 27-36 weeks although, it can be delivered in any stage of pregnancy
* If a woman does not receive the vaccine during pregnancy, she should receive it immediately after giving birth.
* If a woman does not receive the vaccine during pregnancy, she should receive it immediately after giving birth.
|-
|-
| colspan="2" |Typhoid
| colspan="2" align="center" style="background:#DCDCDC;"|Typhoid
|Live and inactivated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live and inactivated
|Inadequate data for specific recommendation
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inadequate data for specific recommendation
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
* Live vaccine (Ty21a) is contraindicated
* Live vaccine (Ty21a) is contraindicated
* Inactivated Vi polysaccharide vaccine should be administered in required clinical setting.
* Inactivated Vi polysaccharide vaccine should be administered in required clinical setting.
|-
|-
| colspan="2" |Varicella
| colspan="2" align="center" style="background:#DCDCDC;"|Varicella
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|Contraindicated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Contraindicated
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|-
|-
| colspan="2" |Yellow fever
| colspan="2" align="center" style="background:#DCDCDC;"|Yellow fever
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|May be used if needed
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |May be used if needed
|Travel and other
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Travel and other
|If the pregnant women is required to travel to a high risk endemic area then it is recommended.
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |If the pregnant women is required to travel to a high risk endemic area then it is recommended.
|-
|-
| colspan="2" |Zoster
| colspan="2" align="center" style="background:#DCDCDC;"|Zoster
|Live
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Live
|Contraindicated
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Contraindicated
|Routine
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |Routine
|
|style="padding: 5px 5px; background: #F5F5F5;" align="left" |
|}
|}
 
==Refernces==
==Refernces==
{{reflist|2}}
{{reflist|2}}

Revision as of 18:25, 4 April 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Immunization prevents illness, disability and death from vaccine-preventable diseases. Vaccines are useful to reduce childhood mortality and morbidity. Vaccination schedule starts at early infancy and it's not complete by age of 6 months. Therefore, most of the children do not have coverage during the early infancy with adequate protection which may predispose them to infections. This gap may result in higher infection related hospitalization and disease complications in early infancy than in older children. Maternal vaccination has became to consideration to cover this gap. However it can protect mother from acquiring infection it is also effective for infant protection.

Immunology

Maternal immunity changes during the pregnancy under influence of hormonal changes. Increased level of estrogen and progesterone are the most important factors for these changes. Increased level of estradiol is associated with increased level of T-helper type 2 cell response compared to type 1 T-cells.[1][2] However, increased level of progesterone may result in decrease in immune response and alteration in immune system.[3][4] Other aspect of immune response such as, phagocytosis and number of neutrophils and monocytes remains unchanged.[4]
These changes (alteration in cell mediated immunity) explain sub-optimal immune response to some certain viral infections such as influenza. Furthermore, it justifies the need for immunization against these infections.[5] Other parts of immune system remains intact during pregnancy and immunosuppresion does not encounter during pregnancy.
Clinical effectiveness of vaccination during pregnancy is maintained and changes in immune balance does not influence their effectiveness.[6][7][8]

Maternal immunization recommendation

Inactivated influenza and combined tetanus-diphteria-acellular pertussis (TDaP) are recommended for pregnant women in the U.S. Hepatitis B and hepatitis E vaccines are recommended in some other countries.
The following table summarize the vaccines and current recommendations for their administration during pregnancy.

Vaccine Type Recommendation for pregnant women Specific consideration
Category Comment
Anthrax Inactivated May be used in women with high risk of exposure; not recommended for

those with low risk of exposure.

Travel and other Generally, inactivated vaccines are safe in pregnancy but anthrax vaccine is reserved for high risk mothers only.
BCG Live Contraindicated Travel and other Live vaccines are contraindicated in pregnancy however, there is no report for BCG adverse effects in pregnancy
HAV Inactivated Recommended for specific indications Routine Indications:
  • History of injection or noninjection illicit drug use
  • Work with HAV-infected primates
  • Work with HAV in a research laboratory
  • Chronic liver disease
  • Receive clotting factor concentrates
  • Travel to or work in countries with high or intermediate endemicity of hepatitis A
HBV Recombinant Recommended for specific indications Routine Indications:
  • If have had a HBsAg-positive sex partner
  • Have had more than one sex partner during the previous 6 mo
  • Have been evaluated or treated for an STD
  • History of recent or current injection-drug use

The recommended schedule is 0, 1, and 6 mo.

HPV Inactivated Not recommended Routine If a woman is found to be pregnant during the administration of an HPV series, the remaining doses should be delayed until after pregnancy is completed.
Influenza Inactivated Recommended Routine Recommended for all women who are or will be pregnant during influenza season.
Live, attenuated Contraindicated Routine Risk of fetal infection
Japanese encephalitis virus Inactivated Inadequate data for specific recommendation Travel and other Theoretical risk for fetus however, it is recommended for pregnant women traveling to a high risk area.
Meningococcal Inactivated
  • Serotype ACWY conjugate vaccine may be used in the case of a specific indication
  • Serotype B vaccine administration should be based on a risk–benefit assessment for the patient
Routine
MMR Live Contraindicated Routine Live vaccines are contraindicated during pregnancy.

If the vaccine is inadvertently given to a pregnant woman, she should be informed of the theoretical risks to the fetus.

However, receipt of the vaccine is not an indication for termination of pregnancy.

Pneumococcal Conjugate

(PCV13)

Inactivated Inadequate data for specific recommendation Routine
Polysaccharide

(PPSV23)

Inactivated Inadequate data for specific recommendation Routine It found to be safe in 2nd and 3rd trimesters. But, it seems that it's not effective to prevent infant pneumococcal infection.(19)
Poliovirus, Inactivated May be used if needed Routine Indicated for high risk women (travel to endemic area or occupational exposure)
Rabies virus Inactivated May be used if needed Travel and other Post-exposure prophylaxis is indicated.
Smallpox Live Recommended after exposure Travel and other Pre-exposure prophylaxis is not recommended.
TDaP Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis style="padding: 5px 5px; background: #F5F5F5;" align="left" |Inactivated Recommended Routine
  • Preferred time: 27-36 weeks although, it can be delivered in any stage of pregnancy
  • If a woman does not receive the vaccine during pregnancy, she should receive it immediately after giving birth.
Typhoid Live and inactivated Inadequate data for specific recommendation Travel and other
  • Live vaccine (Ty21a) is contraindicated
  • Inactivated Vi polysaccharide vaccine should be administered in required clinical setting.
Varicella Live Contraindicated Routine
Yellow fever Live May be used if needed Travel and other If the pregnant women is required to travel to a high risk endemic area then it is recommended.
Zoster Live Contraindicated Routine

Refernces

  1. Lindheimer MD, Cunningham FG (2014). "Pregnancy and infection". N. Engl. J. Med. 371 (11): 1076–7. doi:10.1056/NEJMc1408436#SA3. PMID 25207785.
  2. Straub RH (2007). "The complex role of estrogens in inflammation". Endocr. Rev. 28 (5): 521–74. doi:10.1210/er.2007-0001. PMID 17640948.
  3. Szekeres-Bartho J, Wegmann TG (1996). "A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance". J. Reprod. Immunol. 31 (1–2): 81–95. PMID 8887124.
  4. 4.0 4.1 Robinson DP, Klein SL (2012). "Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis". Horm Behav. 62 (3): 263–71. doi:10.1016/j.yhbeh.2012.02.023. PMC 3376705. PMID 22406114.
  5. Pazos M, Sperling RS, Moran TM, Kraus TA (2012). "The influence of pregnancy on systemic immunity". Immunol. Res. 54 (1–3): 254–61. doi:10.1007/s12026-012-8303-9. PMID 22447351.
  6. Schlaudecker EP, McNeal MM, Dodd CN, Ranz JB, Steinhoff MC (2012). "Pregnancy modifies the antibody response to trivalent influenza immunization". J. Infect. Dis. 206 (11): 1670–3. doi:10.1093/infdis/jis592. PMID 22984116.
  7. Sperling RS, Engel SM, Wallenstein S, Kraus TA, Garrido J, Singh T, Kellerman L, Moran TM (2012). "Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum". Obstet Gynecol. 119 (3): 631–9. doi:10.1097/AOG.0b013e318244ed20. PMC 3327739. PMID 22353963.
  8. Munoz FM, Bond NH, Maccato M, Pinell P, Hammill HA, Swamy GK, Walter EB, Jackson LA, Englund JA, Edwards MS, Healy CM, Petrie CR, Ferreira J, Goll JB, Baker CJ (2014). "Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial". JAMA. 311 (17): 1760–9. doi:10.1001/jama.2014.3633. PMC 4333147. PMID 24794369.